The purpose of this survey is to identify whether or not you had several side effects from your last 131-I therapy and to help identify factors that may have increased, decreased, or prevented these side effects.
The results of this survey may be very valuable in the future management of 131-I therapies. Your responses are voluntary, anonymous, and will not affect your relationship with MedStar Health, Washington Hospital Center, Mayo Clinic, Carolina Medical Center, and/or ThyCa: Thyroid Cancer Survivors' Association, Inc.
If you are a guardian of a minor or another individual who received an 131-I therapy, please complete this survey for that individual.
In advance, thank you for your participation.
The ThyCa Survey Committee
Financial Disclosure: None of the members of this survey committee have received any funding from any organization for the development of this survey.
Committee Members are:
Gary Bloom, Executive Director and Co-Founder ThyCa: Thyroid Cancer Survivors' Association, Inc. Washington, D.C.
Douglas Van Nostrand, MD, FACP, FACNM Committee Chair Director, Division of Nuclear Medicine Washington Hospital Center Professor of Medicine, Georgetown University Hospital Center Washington, D. C.
Bryan McIver, MB PhD Consultant and Chair, Thyroid Group Division of Endocrinology, Mayo Clinic Rochester, Minnesota
Michael T. Brennan, DDS, MHS, FDS RCSEd Associate Chairman Director, Sjögren’s Syndrome and Salivary Disorders Center Carolinas Medical Center Charlotte, North Carolina
Gauri Khorjekar, MBBS Nuclear Medicine Research Coordinator Washington Hospital Center Washington, D.C.
Pejman Kharazi, MD Nuclear Medicine Research Coordinator Division of Nuclear Medicine Washington Hospital Center Washington, D.C.